Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410900 · ClinicalTrials.gov registry record · Phase 1
Vaccine Responsiveness After CAR-T Cell Therapy
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT04410900 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 49 participants.
The verdict
NCT04410900, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase I trial will use the inactivated rabies virus vaccine to assess immune function in patients who previously underwent B cell targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx). A cohort of healthy volunteers will also be enrolled as a comparator group. CARTx is a new treatment for patients with B-cell malignancies (cancer of the B-cells), and the long-term effects of CARTx on immune function are not yet well understood. Learning more about vaccine responsiveness in patients who previously underwent CARTx may help doctors better understand immune function. The findings will guide evidence-based strategies for infection prevention to improve outcomes in this rapidly growing population of high-risk individuals.
Interventions
- PROCEDURE Biospecimen Collection
- BIOLOGICAL Wistar Rabies Virus Strain PM-1503-3M Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410900
The ClinicalTrials.gov registry entry for NCT04410900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04410900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04410900 about?
NCT04410900 is a clinical study titled "Vaccine Responsiveness After CAR-T Cell Therapy". This phase I trial will use the inactivated rabies virus vaccine to assess immune function in patients who previously underwent B cell targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx). A cohort of healthy volunteers will also be enrolled as a comparator group. CARTx is a new ...
What is the current status of trial NCT04410900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2020-08-03. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT04410900?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Wistar Rabies Virus Strain PM-1503-3M Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04410900?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.